By Annette Gaudino, HCV/HIV Project Co-Director, TAG Do you remember how old you were when you stopped believing in the monster under your bed? How many times did you have to look and see nothing there before you finally believed…
By Bryn Gay, HCV Project Director, TAG Access to medicines (A2M) activists have become better coordinated, articulate, and adept in responding to pharmaceutical industry shenanigans that threaten access to affordable medicines since the establishment of harmonized global intellectual property (IP) …
By Khairunisa Suleiman, Technical Co-Lead, Global TB CAB and Suraj Madoori, U.S. and Global Health Policy Director, TAG On Sept. 26, 2018, the world came together at the United Nations General Assembly in New York for the first-ever High-Level Meeting…
By JD Davids, TAGline Guest Editor and Suraj Madoori, U.S. and Global Health Policy Director, TAG As the Trump administration makes noise about the high price of pharmaceuticals while doubling down on its commitment to “protect the engine of American…
This two-page brief explains TAG’s mission, gives information about TAG’s origins, describes how we work, and lists some of our many accomplishments since our founding in 1992.
I want to thank all of you for the support that enabled the successes TAG achieved this past year. Despite a challenging political climate and continued attacks against those living with or at risk of contracting HIV, tuberculosis (TB), or…
Global funding for tuberculosis (TB) research climbed to a previously unreported high of USD $772 million in 2017. This marks the second year in a row that funding for TB research and development (R&D) exceeded $700 million.
Global activists at the 49th Union Conference on Lung Health in The Hague opened up a pop-up TB drug warehouse to warn about the dire public health consequences of a rushed shift from Global Fund supported pooled procurement of tuberculosis (TB) drugs and other health products to domestic funding and national procurement systems.
Activists from around the world called on National TB Programs to discontinue routine use of harmful injectable agents in treatment regimens for drug-resistant tuberculosis, in favor of newer, safer World Health Organization (WHO)-recommended treatments.
Bedaquiline is now recommended as a core part of drug-resistant TB treatment, but price is a major concern to ensuring all who need treatment with bedaquiline receive it. The public has made significant investments in the development and introduction of bedaquiline,…